Optimal control and stability analysis of a glucose-insulin-FFA dynamic model with GLP-1 incretin effects
DOI: https://doi.org/10.3846/mma.2026.24231Abstract
Obesity and its associated metabolic dysregulations, particularly Type 2 Diabetes Mellitus (T2DM), constitute a global health crisis. Understanding the intricate interplay of key metabolic components is crucial for effective management strategies. This study presents a novel mathematical model capturing the dynamic interactions among plasma glucose, insulin, and free fatty acids (FFAs), critically integrating the regulatory influence of Glucagon-Like Peptide-1 (GLP-1).
Through qualitative analysis, we established the model’s physiological relevance and demonstrated the existence of a stable equilibrium point, confirmed by numerical simulations across various initial conditions. Sensitivity analysis revealed that FFA-related parameters (e.g., lipolysis rates and FFA-induced insulin impairment) and insulin secretion/clearance rates profoundly affect glucose homeostasis, underscoring the detrimental role of elevated FFAs in hyperglycemia. Furthermore, we applied optimal control theory, using Pontryagin’s Maximum Principle, to design GLP-1 receptor agonist intervention strategies. We evaluated two scenarios that balance the cost of intervention with the effectiveness of glucose regulation. Results show that GLP-1 agonism effectively lowers glucose and FFA levels, with greater glucose reduction achieved when control cost and glucose deviation are equally weighted.
This research provides a comprehensive mathematical framework for analyzing complex glucose-insulin-FFA-GLP-1 dynamics. Our findings highlight the interconnectedness of insulin sensitivity, lipid metabolism, and incretin action in metabolic health and offer valuable insights for optimizing therapeutic interventions. The developed optimal control strategies suggest potential to improve glycemic control and to inform future clinical approaches to prevent and manage metabolic disorders.
Keywords:
mathematical model, glucose, insulin, free fatty acids, GLP-1, sensitivity analysis, optimal controlHow to Cite
Share
License
Copyright (c) 2026 The Author(s). Published by Vilnius Gediminas Technical University.

This work is licensed under a Creative Commons Attribution 4.0 International License.
References
R.N. Bergman. Toward physiological understanding of glucose tolerance: minimal-model approach. Diabetes, 38(12):1512–1527, 1989. https://doi.org/10.2337/diab.38.12.1512
J. Bonet, Y. Yadav, J. Miles, A. Basu, C. Cobelli, R. Basu and C. Dalla Man. A new oral model of free fatty acid kinetics to assess lipolysis in subjects with and without type 2 diabetes. American Journal of Physiology Endocrinology and Metabolism, 325(2):E163–E170, 2023. https://doi.org/10.1152/ajpendo.00091.2023
A. Brown and E. Tzanakakis. Mathematical modeling clarifies the paracrine roles of insulin and glucagon on the glucose-stimulated hormonal secretion of pancreatic alpha- and beta-cells. Frontiers in Endocrinology, 14:1212749, 2023. https://doi.org/10.3389/fendo.2023.1212749
H. Cheriha, Y. Gati and V.P. Kostov. On Descartes’ rule for polynomials with two variations of signs. Lithuanian Mathematical Journal, 60:456–469, 2020. https://doi.org/10.1007/s10986-020-09491-9
V.B. Chueire and E. Muscelli. Effect of free fatty acids on insulin secretion, insulin sensitivity and incretin effect – a narrative review. Archives of Endocrinology and Metabolism, 65(1):24–31, 1 2021. https://doi.org/10.20945/2359-3997000000313
G.F. Grabner, H. Xie, M. Schweiger and R. Zechner. Lipolysis: cellular mechanisms for lipid mobilization from fat stores. Nature Metabolism, 3(11):1445–1465, 2021. https://doi.org/10.1038/s42255-021-00493-6
D.E. Kelley and L.J. Mandarino. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes, 49(5):677–683, 2000. https://doi.org/10.2337/diabetes.49.5.677
S. Lenhart and J.T. Workman. Optimal Control Applied to Biological Models. Chapman & Hall/CRC, 2007. https://doi.org/10.1201/9781420011418
C. Li, Y. Liu, Y. Wang and X. Feng. Dynamic modeling of the glucose-insulin system with inhibitors impulsive control. Mathematical Methods in the Applied Sciences, 2024. https://doi.org/10.1002/mma.10266
M. Ma and J. Li. Dynamics of a glucose-insulin model. Journal of Biological Dynamics, 16(1):733–745, 2022. https://doi.org/10.1080/17513758.2022.2146769.
S.P. Marso, G.H. Daniels, K. Brown-Frandsen, P. Kristensen, J.F.E. Mann, M.A. Nauck, S.E. Nissen, S. Pocock, N.R. Poulter, L.S. Ravn, W.M. Steinberg, M. Stockner, B. Zinman, R.M. Bergenstal and J.B. Buse. Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(9):311–322, 2016. https://doi.org/10.1056/nejmoa1603827
A.L. Murillo, J. Li and C. Castillo-Chavez. Modeling the dynamics of glucose, insulin, and free fatty acids with time delay: The impact of bariatric surgery on type 2 diabetes mellitus. Mathematical Biosciences and Engineering, 16(5):5765–5787, 2019. https://doi.org/10.3934/mbe.2019288
Y.S. Oh, G.D. Bae, D.J. Baek, E.Y. Park and H.S. Jun. Fatty acidinduced lipotoxicity in pancreatic beta-cells during development of type 2 diabetes. Frontiers in Endocrinology, 9(JUL):384, 2018. https://doi.org/10.3389/fendo.2018.00384
J.O. Olukorode, D.A. Orimoloye, N.O. Nwachukwu, C.N. Onwuzo, P.O. Oloyede, T. Fayemi, O.S. Odunaike, P.S. Ayobami-Ojo, N. Divine, D.J. Alo and C.U. Alex. Recent advances and therapeutic benefits of Glucagon-like Peptide-1 (GLP-1) agonists in the management of type 2 diabetes and associated metabolic disorders. Cureus, 16:e72080, 2024. https://doi.org/10.7759/cureus.72080
S.D. Prato, B. Gallwitz, J.J. Holst and J.J. Meier. The incretin/glucagon system as a target for pharmacotherapy of obesity. Obesity Reviews, 23(2):e13372, 2022. https://doi.org/10.1111/obr.13372
M.S. Rahman, K.S. Hossain, S. Das, S. Kundu, E.O. Adegoke, M.A. Rahman, M. AbdulHannan, M. JamalUddin and M.G. Pang. Role of insulin in health and disease: An update. International Journal of Molecular Sciences, 22(12):6403, 2021. https://doi.org/10.3390/ijms22126403
S. Saber and E. Solouma. Advanced fractional modeling of diabetes: bifurcation analysis, chaos control, and a comparative study of numerical methods AdamsBashforth-Moulton and Laplace-Adomian-Pad´e method. Indian Journal of Physics, 99(13):5151–5169, 2025. https://doi.org/10.1007/s12648-025-03712-y
S. Salwahan, S. Abbas and A. Tridane. Optimal control of a periodically switched epidemic model. International Journal of Dynamics and Control, 13(2):98, 2025. https://doi.org/10.1007/s40435-025-01600-1
A. Shankar, A. Sharma, A. Vinas and R.J. Chilton. GLP-1 receptor agonists and delayed gastric emptying: Implications for invasive cardiac interventions and surgery. Cardiovascular Endocrinology and Metabolism, 14(1):e00321, 2024. https://doi.org/10.1097/XCE.0000000000000321
T.I.A. Sørensen. Forecasting the global obesity epidemic through 2050. The Lancet, 405(10481):756–757, 2025. https://doi.org/10.1016/S0140-6736(25)00260-0
D. Stefanovski, N.M. Punjabi, R.C. Boston and R.M. Watanabe. Insulin action, Glucose homeostasis and free fatty acid metabolism: Insights from a novel model. Frontiers in Endocrinology, 12:625701, 3 2021. https://doi.org/10.3389/fendo.2021.625701
Z. Szekeres, A. Nagy, K. Jahner and E. Szabados. Impact of selected Glucagonlike Peptide-1 receptor agonists on serum lipids, adipose tissue, and muscle metabolism—a narrative review. International Journal of Molecular Sciences, 25(15):8214, 8 2024. https://doi.org/10.3390/ijms25158214
B. Topp, K. Promislow, G. Devries, R.M. Miura and D.T. Finegood. A model of β-cell mass, insulin, and glucose kinetics: pathways to diabetes. Journal of theoretical biology, 206(4):605–619, 2000. https://doi.org/10.1006/jtbi.2000.2150
R.H. Unger. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications. Diabetes, 44(8):863–870, 1995. https://doi.org/10.2337/diab.44.8.863
N. Wieder, J.C. Fried, C. Kim, E.-H. Sidhom, M.R. Brown, J.L. Marshall, C. Arevalo, M. Dvela-Levitt, M. Kost-Alimova, J. Sieber et al. FALCON systematically interrogates free fatty acid biology and identifies a novel mediator of lipotoxicity. Cell metabolism, 35(5):887–905, 2023. https://doi.org/10.1016/j.cmet.2023.03.018
J.P.H. Wilding, R.L. Batterham, S. Calanna, M. Davies, L.F. Van Gaal, I. Lingvay, B.M. McGowan, J. Rosenstock, M.T.D. Tran, T.A. Wadden, S. Wharton, K. Yokote, N. Zeuthen and R.F. Kushner. Once-weekly Semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11):989–1002, 2021. https://doi.org/10.1056/nejmoa2032183
X. Zhao, X. An, C. Yang, W. Sun, H. Ji and F. Lian. The crucial role and mechanism of insulin resistance in metabolic disease. Frontiers in Endocrinology, 14:1149239, 2023. https://doi.org/10.3389/fendo.2023.1149239
Y.F. Zhao. Free fatty acid receptors in the endocrine regulation of glucose metabolism: Insight from gastrointestinal-pancreatic-adipose interactions. Frontiers in Endocrinology, 13:956277, 2022. https://doi.org/10.3389/fendo.2022.956277
Z. Zheng, Y. Zong, Y. Ma, Y. Tian, Y. Pang, C. Zhang and J. Gao. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy, 9(1):234, 2024. https://doi.org/10.1038/s41392-024-01931-z
View article in other formats
Published
Issue
Section
Copyright
Copyright (c) 2026 The Author(s). Published by Vilnius Gediminas Technical University.
License

This work is licensed under a Creative Commons Attribution 4.0 International License.